Catherine A. Shu

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

Catherine A. Shu, Justin F. Gainor, Mark M. Awad et al. · The Lancet Oncology · 2020 · 621 citations

Oncology, Metronomic Therapy, Pathology +6

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Keunchil Park, Eric B. Haura, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2021 · 597 citations · Full text

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

Joshua K. Sabari, Giulia C. Leonardi, Catherine A. Shu et al. · Annals of Oncology · 2018 · 315 citations · Full text

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations

Catherine A. Shu, Malcolm C. Pike, Anjali R. Jotwani et al. · JAMA Oncology · 2016 · 226 citations · Full text

PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens

Jonas J. Heymann, William A. Bulman, David Swinarski et al. · Cancer Cytopathology · 2017 · 205 citations · Full text